Venus Remedies is currently trading at Rs. 170.10, up by 6.80 points or 4.16% from its previous closing of Rs. 163.30 on the BSE.
The scrip opened at Rs. 160.55 and has touched a high and low of Rs. 173.70 and Rs. 160.55 respectively. So far 10807 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 275.95 on 28-Jul-2011 and a 52 week low of Rs. 141.05 on 22-Dec-2011.
Last one week high and low of the scrip stood at Rs. 173.70 and Rs. 160.55 respectively. The current market cap of the company is Rs. 165.61 crore.
The promoters holding in the company stood at 34.71% while Institutions and Non-Institutions held 14.42% and 50.87% respectively.
Venus Remedies has added one more patent to its kitty for Vancoplus, a novel antibiotic formulation to combat Methicillin Resistant Staphylococcus Aureus (MRSA) infections. After Potentox, this is the company’s second patent grant from the Australian Patent office (APO), Government of Australia, and is valid till February 2026.
The total market size of MRSA in the world accounts for $9 billion. At present, it is growing at CAGR of 4.8 percent which is estimated to reach $12.40 billion by 2017. The company expects to grab a fair share of this market within 3 years of launch of its novel research product Vancoplus in all major territories of the world.
Vancoplus, a strategically designed formulation through CVMC technology, is the landmark achievement of Venus Medical Research Center Team. The formulation is the most effective and safe option available in the market to curb the notorious methicillin resistant staphylococcus.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: